Opus Genetics is trading at $4.58, down 5.27%, with no clear company-specific explanation identified for the decline on October 1, 2026.
- The company’s events page lists an Euretina 2026 presentation, but reports no new results and does not establish a connection to the share move.
- The S&P 500 and Nasdaq posted modest gains, not a broad same-direction decline that would explain the drop.